Abstract
Orally administered Madopar (levodopa/benserazide 4∶1) dose-dependently antagonized haloperidol-induced (1 mg/kg s.c.) catalepsy in MPP+-lesioned mice. Pretreatment with a new selective catechol-O-methyltransferase (COMT) inhibitor, tolcapone (30 mg/kg p.o.), slightly potentiated the antagonistic effect of Madopar (15 mg/kg p.o.) on haloperidol-induced catalepsy. The ability of tolcapone to increase the Madopar effect was significantly attenuated by high doses of 3-O-methyldopa (3-OMD) (800 mg/kg i.p.). This might suggest a competitive blockade of the active transport of levodopa through the blood-brain barrier. In conclusion, the inhibitory effect of tolcapone on the O-methylation of levodopa to 3-OMD by COMT is largely due to improved levodopa and dopamine availability in the brain, and to the reduced formation of 3-OMD.
Similar content being viewed by others
References
Feuerstein, C.L., Tanche, M., Serre, F., Gavend, M., Pellat, J., and Perret, J., Acta neurol. scand.56 (1977) 79.
Mena, M.A., Muradas, V., Bazan, E., Reiriz, J., and De Yébenes, J.G., Adv. Neurol.45 (1986) 481.
Reilly, D.K., Rivera-Calimlim, L., and Van Dyke, D., Clin. Pharmac. Ther.28 (1980) 278.
Wade, L.A., and Katzman, R., Life Sci.17 (1975) 131.
Nutt, J.G., and Fellman, J.H., Clin. Neuropharmac.7 (1984) 35.
Männistö, P.T., and Kaakkola, S., Pharmac. Toxic.66 (1990) 317.
Reches, A., Mielke, L.R., and Fahn, S., Neurology32 (1982) 887.
Himori, N., Tanaka, Y., Kurasawa, M., Suzuki, T., Mishima, K., and Akaike, N., Pharmacology48 (1994) 226.
Clark, W.G., Vivonia, C.A., and Baxter, C.F., J. appl. Physiol.25 (1968) 319.
Akaike, N., and Himori, N., Naunyn-Schmiedebergs Arch. Pharmac.347 (1993) 652.
Da Prada, M., Can. J. neurol. Sci.18 (1991) 384.
Zürcher, G., Colzi, A., and Da Prada, M., J. neural Transm. Suppl.32 (1990) 375.
Zürcher, G., Dingemanse, J., and Da Prada, M., Adv. Neurol.60 (1993) 641.
Maj, J., Rogóz, Z., Skuza, G., Sowinska, H., and Superata, J., J. neural. Transm.2 (1990) 101.
Bottiglieri, T., Godfrey, P., Flynn, T., Carney, M.W.P., Toone, B.K., and Reynolds, E.H., J. Neurol. Neurosurg. Psychiat.53 (1990) 1096.
De Vanna, M., and Rigamonti, R., Curr. therap. Res.52 (1992) 478.
Yatsugi, S., Yamamoto, T., Ohno, M., and Ueki, S., Eur. J. Pharmac.166 (1989) 231.
Hirata, F., and Axelrod, J., Nature275 (1978) 219.
Strittmatter, W.J., Hirata, F. and Axelrod, J., Biochem. biophys. Res. Commun.88(1979) 147.
Cimino, M., Vantini, G., Algeri, S., Curatola, G., Pezzoli, C., and Stramentionoli, G., Life Sci.34 (1984) 2029.
Muccioli, G., Scordamaglia, A., Bertacco, S., and Di Carlo, R., Eur. J. Pharmac.227 (1992) 293.
Curcio, M., Catto, E., Stramentinoli, G., and Algeri, S., Prog. Neuropsychopharmac.2 (1978) 65.
Katayama, Y., Shimizu, J., Memezawa, H., Minamisawa, H. et al., Brain Nerve, Tokyo37 (1985) 243 (in Japanese).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Himori, N., Mishima, K. The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP+-lesioned mice. Experientia 50, 939–942 (1994). https://doi.org/10.1007/BF01923483
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01923483